About this trial
In order to improve the clinical effect and find a new safe and effective treatment model for advanced recurrent cervical cancer, this study explored the efficacy level safety of pemetrexed, carboplatin, recombinant human adenovirus type 5, and AK104 regimen in recurrent and refractory advanced cervical cancer. For some patients with immune-resistant cervical cancer, combination chemotherapy and oncolytic virus therapy can promote the transformation of cold tumors into hot tumors, eliminate and then reverse the suppressor factors of immune resistance, and break the dilemma of immunotherapy drug resistance, which is a new method and strategy under immunotherapy drug resistance.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial design
Single group
Treatments tested in this trial
AK104
DrugPD-1/CTLA-4 bispecific antibody
Recombinant Human Adenovirus 5 Injection
DrugRecombinant Human Adenovirus 5 Injection
Treatment groups
Trial outcomes
Primary outcomes
ORR
Objective Response Rate
Secondary outcomes
PFS
Progression Free Survival
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Fujian Cancer Hospital
Lead sponsor
Zhangzhou Municipal Hospital of Fujian Province
Collaborator